SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report. The inaugural report provides an overview of Legend Biotech’s ESG program and reporting in alignment with the Sustainable Accounting Standards Board (“SASB”) Biotechnology and Pharmaceutical sector standards, the Company’s ESG data collection and disclosure roadmap, and future growth areas in its ESG journey.
“At Legend Biotech, we are united by our mission to deliver life-saving treatments to patients with intractable and incurable diseases. As one of the largest global cell therapy research and development teams in the industry, sustainable business practices are integral to helping us achieve this goal,” said Ying Huang, Chief Executive Officer of Legend Biotech. “We are proud to share our inaugural ESG report, highlighting our commitment to patients, employees, and our communities. This report marks a foundational step in our ESG journey, which we look forward to building upon in the years ahead.”
Key pillars of Legend’s ESG program include:
-
Caring for Patients, Delivering Transformative Innovations
With more than $1 billion invested in R&D since its inception and ongoing collaborations with leading academic institutions, major hospitals, and industry leaders, Legend Biotech’s dedication to cutting-edge and ethical R&D fuels its pursuit of groundbreaking innovations. The Company prioritizes patient access and well-being throughout the treatment journey by engaging with patient advocacy organizations, investing in commercial presence and production capacity to ensure a strong supply chain, and utilizing a comprehensive patient support program. -
Engaging with Employees and Communities
The Company’s successes would not be possible without the dedication of a talented and passionate workforce. Legend Biotech is proud to report that, based on its most recent annual employee engagement survey, 85% of employees feel their work is meaningful. The Company cultivates a workplace where diverse backgrounds and ideas drive innovation and focuses on providing employees with a meaningful career path through dedicated talent retention, professional development, and community engagement opportunities. -
Fostering Operational Efficiency and Integrity
Legend Biotech prioritizes operational excellence, employee well-being, and resource optimization through robust environmental, health, and safety (EHS) management. The Company’s new chimeric antigen receptor T-cell (CAR-T) facility in Ghent, Belgium, is equipped with state-of-the-art ecological efficiency features, and it will employ the same high safety standards observed at its three U.S. sites, including frequent inspections, incident and emissions tracking, and comprehensive training. To promote accountability to patients, shareholders, and the broader business, Legend Biotech has implemented strong corporate governance practices and a multi-faceted, risk-based cybersecurity and data privacy program aligned with business objectives.
Legend Biotech’s 2023 ESG Report is available on the Company’s website in the About section at www.legendbiotech.com.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at https://legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on March 19, 2024 and Legend Biotech’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts
INVESTOR:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS:
Alexandra Ventura
Tel: (732) 850-5598
media@legendbiotech.com